PROCRIT® is indicated for the treatment of anemia due to zidovudine administered at ≤ 4200 mg/week in patients with HIV infection with endogenous serum erythropoietin levels of ≤ 500 mUnits/mL.
PROCRIT® has not been shown to improve quality of life, fatigue, or patient well-being.
PROCRIT® is not indicated for use:
Percentage of transfusion-dependent patients who became transfusion independent after PROCRIT®
HIV=human immunodeficiency virus; SC=subcutaneously; TIW=3 times weekly; U=units.
WARNINGS: ESAs INCREASE THE RISK OF DEATH, MYOCARDIAL INFARCTION, STROKE, VENOUS THROMBOEMBOLISM, THROMBOSIS OF VASCULAR ACCESS AND TUMOR PROGRESSION OR RECURRENCE
Expand the Important Safety Information at the bottom of the page to see the complete Boxed Warnings.
Adverse reactions with an incidence of ≥1% in patients treated with PROCRIT® were:
Adverse reactions in zidovudine-treated patients with HIV infection1
|ADVERSE REACTION||PROCRIT® (n=144)||Placebo (n=153)|
|INJECTION SITE IRRITATION||7%||4%|
|RESPIRATORY TRACT CONGESTION||1%||Not reported|
|PULMONARY EMBOLISM||1%||Not reported|